ELECTROLITO CONCENTRADO
Fosfato de potasio
Ficha de consulta para farmacia hospitalaria: indicaciones, preparación, dilución, estabilidad y compatibilidad de fosfato de potasio, con la fuente oficial de cada dato.
- Medicamento de alto riesgo
También conocido como: dibasic potassium phosphate / potassium phosphate, Fosfato de potasio concentrado, Fosfatos de potasio
Presentación
Concentrado 3 mmol P / 4.4 mEq K por mL — documentado: Cipla (FDA)
| Producto de referencia | Titular | Vía | Fuente |
|---|---|---|---|
| Potassium Phosphates | Cipla USA Inc. | Intravenous | FDA (DailyMed) |
¿Para qué sirve fosfato de potasio? Indicaciones autorizadas
1 INDICATIONS AND USAGE Potassium phosphates injection is indicated as a source of phosphorus: in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. Potassium phosphates injection is a phosphorus replacement product indicated as a source of phosphorus: in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. ( 1 ) for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. ( 1 )
FDA (DailyMed) · Potassium Phosphates · Indications and usage · texto original en inglés
Dosis máximas y límites de fosfato de potasio
Límites que la fuente establece para un contexto concreto. Una dosis recomendada no equivale a una dosis máxima; la posología completa por indicación, edad y peso está en la app.
| Contexto | Límite | Condiciones y cita |
|---|---|---|
| Etiqueta FDA citada · dosis inicial o única de reposición | 45 mmol de fósforo (66 mEq de potasio) | La pauta se basa en fósforo sérico y peso; considerar función renal y carga de potasio. No confundir mmol de fósforo con mEq de potasio, ni este techo con dosis diaria de nutrición parenteral.«The maximum initial or single dose of phosphorus is 45 mmol (potassium 66 mEq)» · FDA (DailyMed), Dosage and administration |
Contraindicaciones de fosfato de potasio
4 CONTRAINDICATIONS Potassium phosphates injection is contraindicated in patients with: hyperkalemia [see Warning and Precautions ( 5.3 )] severe renal impairment (eGFR less than 30 mL/min/1.73m2) or end stage renal disease [see Warning and Precautions ( 5.3 )] hyperphosphatemia [see Warning and Precautions ( 5.4 )] hypercalcemia or significant hypocalcemia [see Warning and Precautions ( 5.4 )] hyperkalemia ( 4 ) hyperphosphatemia ( 4 ) hypercalcemia or significant hypocalcemia ( 4 ) severe renal impairment (eGFR less than 30 mL/min/1.73m 2 ) or end stage renal disease ( 4 )
FDA (DailyMed) · Potassium Phosphates · Contraindications · texto original en inglés
Ajuste en insuficiencia renal
Parámetro que cita la fuente: TFGe (filtrado glomerular estimado)
In patients with moderate renal impairment (eGFR ≥30 mL/min/1.73 m2 to <60 mL/min/1.73 m2), start at the low end of the dose range [see Use in Specific Populations ( 8.6 )] .
FDA (DailyMed) · Potassium Phosphates · Dosage and administration · texto original en inglés
Recommended Daily Dosage of Potassium Phosphates Injection for Parenteral Nutrition for Adults and Pediatric Patients Patient Population Generally Recommended Phosphorus Daily Dosage (Potassium Content) Preterm and Term Infants Less than 12 Months 2 mmol/kg/day (potassium 2.9 mEq/kg/day) Pediatric Patients 1 year to Less Than 12 years 1 mmol/kg/day; up to 40 mmol/day (potassium 1.5 mEq/kg/day; up to 58.7 mEq/day) Adults and Pediatric Patients 12 Years of Age and Older 20 mmol/day to 40 mmol/day a (potassium 29.3 mEq/day to 58.7 mEq/day) a In patients with moderate renal impairment (eGFR ≥30 mL/min/1.73 m 2 to <60 mL/min/1.73 m 2 ), start at the low end of the dosage range.
FDA (DailyMed) · Potassium Phosphates · Dosage and administration · texto original en inglés
Because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with potassium phosphates injection may be at higher risk of aluminum toxicity. [see Warnings and Precautions ( 5.5 )] . 8.5 Geriatric Use In general, dose selection of potassium phosphates injection for an elderly patient should be cautious, starting at the low end of the dosing range because of the greater…
FDA (DailyMed) · Potassium Phosphates · Use in specific populations · texto original en inglésLeer la sección completa
Because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with potassium phosphates injection may be at higher risk of aluminum toxicity. [see Warnings and Precautions ( 5.5 )] . 8.5 Geriatric Use In general, dose selection of potassium phosphates injection for an elderly patient should be cautious, starting at the low end of the dosing range because of the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. It may be useful to monitor renal function during treatment [see Use in Specific Populations ( 8.6 )] . 8.6 Renal Impairment Potassium and phosphorus are known to be substantially excreted by the kidney and the risk of adverse reactions to potassium phosphates injection may be greater in patients with impaired renal function [see Warnings and Precautions ( 5.3 , 5.4 , 5.5 )] . Potassium phosphates injection is contraindicated due to the risk of hyperkalemia in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m 2 ) or end stage renal disease [see Contraindications ( 4 )] . In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m 2 to < 60 mL/min/1.73 m 2 ), start at the low end of the dosage range and monitor serum potassium, phosphorus, calcium, and magnesium concentrations [see Dosage and Administration ( 2.2 , 2.4 )].
Ajuste en insuficiencia hepática
Because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with potassium phosphates injection may be at higher risk of aluminum toxicity. [see Warnings and Precautions ( 5.5 )] . 8.5 Geriatric Use In general, dose selection of potassium phosphates injection for an elderly patient should be cautious, starting at the low end of the dosing range because of the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
FDA (DailyMed) · Potassium Phosphates · Use in specific populations · texto original en inglés
Reconstitución de fosfato de potasio
No requiere.
Dilución de fosfato de potasio
SIEMPRE diluir antes de usar.
Administración de fosfato de potasio
Solo infusión IV con bomba. Nunca en bolo.
Estabilidad y periodo de validez
| Condición | Tiempo | Nota |
|---|---|---|
| Diluido, 20–25 °C | 4 h | |
| Diluido, 2–8 °C | 14 días | 14 días. |
Compatibilidad de fosfato de potasio
Compatible con
- SF 0.9%
- Glucosa 5%
Incompatible con
- Sales de calcio (precipitado de fosfato de calcio, causa de embolias pulmonares mortales)
Conservación y protección de la luz
A temperatura ambiente.
El producto no requiere protección de la luz; la nutrición parenteral que lo contenga debe protegerse de la luz durante su almacenamiento.
Advertencias
- MEDICAMENTO DE ALTO RIESGO: concentrado de potasio.
- Prescribir en mmol de fosfato y considerar el potasio aportado.
- En nutrición parenteral, revisar la solubilidad calcio-fósforo.
Fuentes
- FDA (DailyMed) · Potassium PhosphatesCipla USA Inc. · Fosfatos de potasio (envase de farmacia y viales) · versión 2025-02-28
Interacciones de fosfato de potasio
5 medicamentos del catálogo con una interacción documentada en sus fichas oficiales. Abre cada una para ver el efecto, la recomendación y su fuente.
- Cloruro de calcioMayor
- DigoxinaMayor
- EspironolactonaMayor
- Gluconato de calcioMayor
- TacrolimusMayor
Identificación
- RxNorm
- 1008224
Información de consulta profesional extraída de las fichas técnicas y etiquetas oficiales citadas. Las condiciones de preparación, estabilidad y administración dependen del producto concreto: verifica el documento del producto que utilizas. No sustituye el criterio clínico ni la valoración del paciente.